Xuefeng Leng, MD, explains results from the phase 3 SCIENCE trial, evaluating neoadjuvant chemoradiotherapy and chemotherapy with sintilimab for esophageal squamous cell carcinoma.
9th Annual Blood Cover Art Contest is now open. In recognition of authors who published in Blood and images used in advancement of science, we…
Panelists discuss how emerging treatment strategies, including the use of CDK4/6 inhibitors and personalized risk stratification, are transforming the management of high-risk HR+/HER2– early-stage breast…
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Although our findings suggest that alcohol drinking does not modify the PRS-based genetic risk of breast cancer among White and Black women with lower alcohol…
After a phase 3 study showed a promising pCR rate with HLX11, the pertuzumab biosimilar’s BLA has been accepted for review by the FDA.
Key PointseIF4E/XPO1 collaboratively transport GATA-3 and GATA-3 targets and are thus therapeutic vulnerabilities in GATA-3–driven TCLs.Impaired eIF4E/XPO1
PURPOSEApproximately 50% of patients with advanced Merkel cell carcinoma (MCC) have primary or acquired resistance to PD-(L)1 blockade, which may be overcome using combination immune…
Marwan G. Fakih, MD, discussed the implications of the findings from the phase 2 study for patients with microsatellite stable metastatic colorectal cancer without liver…
